Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

ART6043

Source date not recordedAnalyse record ↗

DNA polymerase theta inhibitor in the recruiting Phase 1/2a POLKA solid-tumor study.

Modality
oral small-molecule DNA polymerase theta inhibitor
Availability (US)
Phase 1/2a POLKA study Recruiting; randomized Phase 2 combination portion underway
Biomarkers
dose-limiting toxicities; adverse events; pharmacokinetics; RECIST response; progression-free survival
Hallmark targeted
genomic instability, DNA repair, homologous-recombination deficiency
Kind
investigational drug
Clinical trials
NCT05898399 — Phase 1/Phase 2, Recruiting on September 15, 2026 update